Radiprodil
| Clinical data | |
|---|---|
| Other names | RGH-896; RGH896 |
| Routes of administration | Oral[1] |
| Drug class | NR2B subunit-containing NMDA receptor negative allosteric modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H20FN3O4 |
| Molar mass | 397.406 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Radiprodil (INN; developmental code name RGH-896) is an NR2B (GluN2B; GRIN2B) subunit-selective NMDA receptor negative allosteric modulator which is under development for the treatment of neurodevelopmental disorders, focal cortical dysplasia, tuberous sclerosis, behavioral disorders, and seizures.[1][2][3] It is taken orally.[1] The drug is being developed by GRIN Therapeutics.[1] As of December 2025, it is in phase 3 clinical trials for neurodevelopmental disorders, phase 1/2 trials for focal cortical dysplasia and tuberous sclerosis, and phase 1 trials for behavioral disorders and seizures.[1] The drug was first described in the scientific literature by 2003.[4]
See also
References
- ^ a b c d e "GRIN Therapeutics". AdisInsight. 28 December 2025. Retrieved 16 January 2026.
- ^ Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, et al. (March 2020). "Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome". Annals of Clinical and Translational Neurology. 7 (3): 343–352. doi:10.1002/acn3.50998. PMC 7085998. PMID 32106360.
- ^ Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, et al. (September 2017). "GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors". Neuropharmacology. 123: 322–331. doi:10.1016/j.neuropharm.2017.05.017. PMID 28533163.
- ^ Farkas S, Horvath C, Nagy J (2003). RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Society for Neuroscience. Washington, DC. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner.